Scott Smith, MD, PhD, FACP

Medicine

Hematology/Oncology
Professor

Languages Spoken

English

Clinical Expertise

  • Bone Marrow Disorders
  • Leukemia
  • Non-Hodgkin's Lymphoma
  • Refractory Lymphoma

About Dr. Smith

Interests
Fly Fishing;Mountain Biking;Hiking;Reading;Golf

Medical Education

Medical School
Wayne State University School of Medicine
Residency
Loyola University Medical Center - Internal Medicine: General
Fellowship
Loyola University Medical Center - Hematology/Oncology

Board Certification

American Board of Internal Medicine Subspecialty Hematology

Research

  • Evaluation of Risk Factors for Clostridium difficile Infection in Hematopoietic Stem Cell Transplant Recipients Scardina, T. L.; Kang Martinez, E.; Balasubramanian, N.; Fox-Geiman, M.; Smith, S. E.; Parada, J. P., Pharmacotherapy
  • Safety and tolerability of idelalisib lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials, Smith, S. M.; Pitcher, B. N.; Jung, S. H.; Bartlett, N. L.; Wagner-Johnston, N.; Park, S. I.; Richards, K. L.; Cashen, A. F.; Jaslowski, A.; Smith, S. E.; Cheson, B. D.; Hsi, E.; Leonard, J. P., The Lancet.Haematology
  • Safety and tolerability of idelalisib lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials, Smith, S. M.; Pitcher, B. N.; Jung, S. H.; Bartlett, N. L.; Wagner-Johnston, N.; Park, S. I.; Richards, K. L.; Cashen, A. F.; Jaslowski, A.; Smith, S. E.; Cheson, B. D.; Hsi, E.; Leonard, J. P., The Lancet.Haematology
View All ResearchShow Less
  • A multicenter phase II study of sepantronium bromide (YM155) plus rituximab in patients with relapsed aggressive B-cell Non-Hodgkin lymphoma Papadopoulos, K. P.; Lopez-Jimenez, J.; Smith, S. E.; Steinberg, J.; Keating, A.; Sasse, C.; Jie, F.; Thyss, A., Leukemia & lymphoma
  • Busulfan Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma, Rodriguez, T. E.; Hari, P.; Stiff, P. J.; Smith, S. E.; Sterrenberg, D.; Vesole, D. V., Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma Chen, R.; Gopal, A. K.; Smith, S. E.; Ansell, S. M.; Rosenblatt, J. D.; Savage, K. J.; Connors, J. M.; Engert, A.; Larsen, E. K.; Huebner, D.; Fong, A.; Younes, A., Blood
  • Phase I trial of rituximab lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103, Ujjani, C. S.; Jung, S. H.; Pitcher, B.; Martin, P.; Park, S. I.; Blum, K. A.; Smith, S. M.; Czuczman, M.; Davids, M. S.; Levine, E.; Lewis, L. D.; Smith, S. E.; Bartlett, N. L.; Leonard, J. P.; Cheson, B. D., Blood
  • Phase I trial of rituximab lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103, Ujjani, C. S.; Jung, S. H.; Pitcher, B.; Martin, P.; Park, S. I.; Blum, K. A.; Smith, S. M.; Czuczman, M.; Davids, M. S.; Levine, E.; Lewis, L. D.; Smith, S. E.; Bartlett, N. L.; Leonard, J. P.; Cheson, B. D., Blood
  • Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable Landsburg, D. J.; Falkiewicz, M. K.; Petrich, A. M.; Chu, B. A.; Behdad, A.; Li, S.; Medeiros, L. J.; Cassaday, R. D.; Reddy, N. M.; Bast, M. A.; Vose, J. M.; Kruczek, K. R.; Smith, S. E.; Patel, P.; Hernandez-Ilizaliturri, F.; Karmali, R.; Rajguru, S.; Yang, D. T.; Maly, J. J.; Blum, K. A.; Zhao, W.; Vanslambrouck, C.; Nabhan, C., British journal of haematology
  • A prospective investigation of cell dose in single-unit umbilical cord blood transplantation for adults with high-risk hematologic malignancies Sobol, U.; Go, A.; Kliethermes, S.; Bufalino, S.; Rodriguez, T.; Smith, S.; Parthasarathy, M.; Stiff, P., Bone marrow transplantation
  • Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignancies Forero-Torres, A.; Bartlett, N. L.; Berryman, R. B.; Chen, R.; Matous, J. V.; Fanale, M. A.; O'Connor, O. A.; Olshefski, R.; Smith, S. E.; Huebner, D.; Levine, P. L.; Grove, L. E.; Gopal, A. K., Leukemia & lymphoma
  • Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy Gopal, A. K.; Bartlett, N. L.; Forero-Torres, A.; Younes, A.; Chen, R.; Friedberg, J. W.; Matous, J. V.; Shustov, A. R.; Smith, S. E.; Zain, J.; O'Meara, M. M.; Fanale, M. A., Leukemia & lymphoma
  • Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma Gopal, A. K.; Chen, R.; Smith, S. E.; Ansell, S. M.; Rosenblatt, J. D.; Savage, K. J.; Connors, J. M.; Engert, A.; Larsen, E. K.; Chi, X.; Sievers, E. L.; Younes, A., Blood
  • Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis Petrich, A. M.; Gandhi, M.; Jovanovic, B.; Castillo, J. J.; Rajguru, S.; Yang, D. T.; Shah, K. A.; Whyman, J. D.; Lansigan, F.; Hernandez-Ilizaliturri, F. J.; Lee, L. X.; Barta, S. K.; Melinamani, S.; Karmali, R.; Adeimy, C.; Smith, S.; Dalal, N.; Nabhan, C.; Peace, D.; Vose, J.; Evens, A. M.; Shah, N.; Fenske, T. S.; Zelenetz, A. D.; Landsburg, D. J.; Howlett, C.; Mato, A.; Jaglal, M.; Chavez, J. C.; Tsai, J. P.; Reddy, N.; Li, S.; Handler, C.; Flowers, C. R.; Cohen, J. B.; Blum, K. A.; Song, K.; Sun, H. L.; Press, O.; Cassaday, R.; Jaso, J.; Medeiros, L. J.; Sohani, A. R.; Abramson, J. S., Blood
  • Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial Jain, N.; Curran, E.; Iyengar, N. M.; Diaz-Flores, E.; Kunnavakkam, R.; Popplewell, L.; Kirschbaum, M. H.; Karrison, T.; Erba, H. P.; Green, M.; Poire, X.; Koval, G.; Shannon, K.; Reddy, P. L.; Joseph, L.; Atallah, E. L.; Dy, P.; Thomas, S. P.; Smith, S. E.; Doyle, L. A.; Stadler, W. M.; Larson, R. A.; Stock, W.; Odenike, O., Clinical cancer research : an official journal of the American Association for Cancer Research
  • Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies Bartlett, N. L.; Chen, R.; Fanale, M. A.; Brice, P.; Gopal, A.; Smith, S. E.; Advani, R.; Matous, J. V.; Ramchandren, R.; Rosenblatt, J. D.; Huebner, D.; Levine, P.; Grove, L.; Forero-Torres, A., Journal of hematology & oncology
  • Seven-year follow-up of allogeneic transplant using BCNU etoposide, cytarabine and melphalan chemotherapy in patients with Hodgkin lymphoma after autograft failure: importance of minimal residual disease, Sobol, U.; Rodriguez, T.; Smith, S.; Go, A.; Vimr, R.; Parthasarathy, M.; Guo, R.; Stiff, P., Leukemia & lymphoma
  • Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies Han, T. H.; Chen, R.; Advani, R.; Berryman, R. B.; Smith, S. E.; Forero-Torres, A.; Rosenblatt, J. D.; Smith, M. R.; Zain, J.; Hunder, N. N.; Engert, A., CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • High-dose vincristine sulfate liposome injection for advanced relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia, O'Brien, S.; Schiller, G.; Lister, J.; Damon, L.; Goldberg, S.; Aulitzky, W.; Ben-Yehuda, D.; Stock, W.; Coutre, S.; Douer, D.; Heffner, L. T.; Larson, M.; Seiter, K.; Smith, S.; Assouline, S.; Kuriakose, P.; Maness, L.; Nagler, A.; Rowe, J.; Schaich, M.; Shpilberg, O.; Yee, K.; Schmieder, G.; Silverman, J. A.; Thomas, D.; Deitcher, S. R.; Kantarjian, H., Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective randomized trial of aprepitant used with highly emetogenic preparative regimens, Stiff, P. J.; Fox-Geiman, M. P.; Kiley, K.; Rychlik, K.; Parthasarathy, M.; Fletcher-Gonzalez, D.; Porter, N.; Go, A.; Smith, S. E.; Rodriguez, T. E., Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome Raza, A.; Galili, N.; Smith, S. E.; Godwin, J.; Boccia, R. V.; Myint, H.; Mahadevan, D.; Mulford, D.; Rarick, M.; Brown, G. L.; Schaar, D.; Faderl, S.; Komrokji, R. S.; List, A. F.; Sekeres, M., Cancer
  • A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era Evens, A. M.; Helenowski, I.; Ramsdale, E.; Nabhan, C.; Karmali, R.; Hanson, B.; Parsons, B.; Smith, S.; Larsen, A.; McKoy, J. M.; Jovanovic, B.; Gregory, S.; Gordon, L. I.; Smith, S. M., Blood
  • A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era Evens, A. M.; Helenowski, I.; Ramsdale, E.; Nabhan, C.; Karmali, R.; Hanson, B.; Parsons, B.; Smith, S.; Larsen, A.; McKoy, J. M.; Jovanovic, B.; Gregory, S.; Gordon, L. I.; Smith, S. M., Blood
  • Analysis of very elderly (>/=80 years) non-hodgkin lymphoma: impact of functional status and co-morbidities on outcome Nabhan, C.; Smith, S. M.; Helenowski, I.; Ramsdale, E.; Parsons, B.; Karmali, R.; Feliciano, J.; Hanson, B.; Smith, S.; McKoy, J.; Larsen, A.; Hantel, A.; Gregory, S.; Evens, A. M., British journal of haematology
  • Analysis of very elderly (>/=80 years) non-hodgkin lymphoma: impact of functional status and co-morbidities on outcome Nabhan, C.; Smith, S. M.; Helenowski, I.; Ramsdale, E.; Parsons, B.; Karmali, R.; Feliciano, J.; Hanson, B.; Smith, S.; McKoy, J.; Larsen, A.; Hantel, A.; Gregory, S.; Evens, A. M., British journal of haematology
  • Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS) Raza, A.; Galili, N.; Mulford, D.; Smith, S. E.; Brown, G. L.; Steensma, D. P.; Lyons, R. M.; Boccia, R.; Sekeres, M. A.; Garcia-Manero, G.; Mesa, R. A., Journal of hematology & oncology
  • Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma Younes, A.; Gopal, A. K.; Smith, S. E.; Ansell, S. M.; Rosenblatt, J. D.; Savage, K. J.; Ramchandren, R.; Bartlett, N. L.; Cheson, B. D.; de Vos, S.; Forero-Torres, A.; Moskowitz, C. H.; Connors, J. M.; Engert, A.; Larsen, E. K.; Kennedy, D. A.; Sievers, E. L.; Chen, R., Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation Gopal, A. K.; Ramchandren, R.; O'Connor, O. A.; Berryman, R. B.; Advani, R. H.; Chen, R.; Smith, S. E.; Cooper, M.; Rothe, A.; Matous, J. V.; Grove, L. E.; Zain, J., Blood
  • TNF-inhibition with etanercept for graft-versus-host disease prevention in high-risk HCT: lower TNFR1 levels correlate with better outcomes Choi, S. W.; Stiff, P.; Cooke, K.; Ferrara, J. L.; Braun, T.; Kitko, C.; Reddy, P.; Yanik, G.; Mineishi, S.; Paczesny, S.; Hanauer, D.; Pawarode, A.; Peres, E.; Rodriguez, T.; Smith, S.; Levine, J. E., Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era Evens, A. M.; David, K. A.; Helenowski, I.; Nelson, B.; Kaufman, D.; Kircher, S. M.; Gimelfarb, A.; Hattersley, E.; Mauro, L. A.; Jovanovic, B.; Chadburn, A.; Stiff, P.; Winter, J. N.; Mehta, J.; Van Besien, K.; Gregory, S.; Gordon, L. I.; Shammo, J. M.; Smith, S. E.; Smith, S. M., Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era Evens, A. M.; David, K. A.; Helenowski, I.; Nelson, B.; Kaufman, D.; Kircher, S. M.; Gimelfarb, A.; Hattersley, E.; Mauro, L. A.; Jovanovic, B.; Chadburn, A.; Stiff, P.; Winter, J. N.; Mehta, J.; Van Besien, K.; Gregory, S.; Gordon, L. I.; Shammo, J. M.; Smith, S. E.; Smith, S. M., Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium Smith, S. M.; van Besien, K.; Karrison, T.; Dancey, J.; McLaughlin, P.; Younes, A.; Smith, S.; Stiff, P.; Lester, E.; Modi, S.; Doyle, L. A.; Vokes, E. E.; Pro, B., Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium Smith, S. M.; van Besien, K.; Karrison, T.; Dancey, J.; McLaughlin, P.; Younes, A.; Smith, S.; Stiff, P.; Lester, E.; Modi, S.; Doyle, L. A.; Vokes, E. E.; Pro, B., Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • The impact of pharmacotherapy on depression and quality of life in patients undergoing a bone marrow transplant (BMT). Mumby, P. B.; Garcia, C.; Trivedi-Purohit, R.; Gourvitz, R.; Rychlik, K.; Rodriguez, T.; Smith, S. E.; Toor, A. A.; Rao, M.; Stiff, P. J., ASCO Meeting Abstracts
  • Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets) a novel glutathione analog prodrug, in patients with myelodysplastic syndrome, Raza, A.; Galili, N.; Smith, S.; Godwin, J.; Lancet, J.; Melchert, M.; Jones, M.; Keck, J. G.; Meng, L.; Brown, G. L.; List, A., Blood
  • Feasibility of conditioning with thymoglobulin and reduced intensity TBI to reduce acute GVHD in recipients of allogeneic SCT Toor, A.; Rodriguez, T.; Bauml, M.; Mathews, H.; Shanti, S.; Senitzer, D.; Kini, A.; Norton, J.; Parthasarathy, M.; Mohideen, N.; Petrowsky, C.; Bonilla, B.; Smith, S.; Stiff, P., Bone marrow transplantation
  • Hydroxyurea azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial, Nand, S.; Godwin, J.; Smith, S.; Barton, K.; Michaelis, L.; Alkan, S.; Veerappan, R.; Rychlik, K.; Germano, E.; Stiff, P., Leukemia & lymphoma
  • The administration of polymerized human hemoglobin (Pyridoxylated) to a Jehovah's Witness after submyeloablative stem cell transplantation complicated by delayed graft failure Smith, S. E.; Toor, A.; Rodriguez, T.; Stiff, P., Comprehensive therapy
  • Megakaryoblastic leukemia with involvement of the pleural fluid. Farray, D.; Al-Masri, H.; Hattersley, E.; Smith, S. E., American Journal of Hematology
  • Acute myeloid leukemia in the older patient Godwin, J. E.; Smith, S. E., Critical Reviews in Oncology-Hematology